Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/17/20 (What's New)

Summary

  • Studies evaluating switches in suppressed patients receiving stable lopinavir/ritonavir-based antiretroviral therapy switched to raltegravir found improvements in serum lipids
    • SWITCHMRK studies[Eron 2010] were stopped at Week 24 because of increased risk of virologic failure; however, the SPIRAL study[Martínez 2010] did not demonstrate such a difference

Action required

Keywords: Adherence, Cardiovascular Disease, Dyslipidemia, Fat Perturbations, Switch Strategies, Treatment Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.